Supplementation with Coenzyme Q10 (CoQ10) as Prophylaxis in Adult Patients with Migraine: A Brief Updated Meta-Analysis
DOI:
https://doi.org/10.63969/43673716Keywords:
migraine, coenzyme Q10, prophylaxis, meta-analysis, randomized controlled trialsAbstract
Introduction: Migraine is a common and disabling neurological disorder, largely related to pathophysiological mechanisms involving oxidative stress and mitochondrial dysfunction. Coenzyme Q10 (CoQ10), due to its role in the mitochondrial electron transport chain, has been proposed as a prophylactic treatment strategy; however, the available evidence remains inconsistent. Methods: A systematic review and meta-analysis of double-blind randomized controlled trials was conducted, comparing CoQ10 supplementation with placebo in adults with migraine diagnosed according to International Headache Society (IHS) criteria. Primary outcome: Monthly frequency of migraine attacks after treatment. Secondary outcome: Pain severity during migraine attacks. Random- effects models were applied. Methodological quality was assessed using RoB 2.0, and certainty of evidence was evaluated with the GRADE approach. Results: Seven randomized clinical trials involving 510 patients were included. Five studies (329 patients) demonstrated a significant reduction in monthly migraine frequency in favor of CoQ10 (MD: −0.84; 95% CI −1.62 to −0.05; p = 0.04; I² = 0%). Additionally, five trials (324 patients) showed a moderate but statistically significant reduction in pain severity measured by the visual analog scale (VAS) (SMD: −0.17; 95% CI −0.33 to −0.01; p = 0.05; I² = 0%). Conclusions: CoQ10 supplementation is associated with a reduction in monthly migraine attack frequency in adults, supporting its use as a complementary prophylactic strategy in migraine.
Downloads
References
Ellouz E, Ketata I. Prophylactic Effectiveness of Coenzyme Q10 for Migraine in Adults: A Systematic Review and Meta-Analysis of Double- Blinded Randomized Clinical Trials. Trad Integr Med. 2025; 10(3): p. 228- 240.
Amiri P, Kazeminasab S, Nejadghaderi S, et al. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022; 12: p. 800605.
Wang Y, Wang Y, Yue G, Zhao Y. Energy metabolism disturbance in migraine: From a mitochondrial point of view. Front Physiol. 2023; 14: p. 1133528.
Sazali S, Badrin S, Norhayati M, Idris N. Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta- analysis. BMJ Open. 2021; 11(1): p. e039358.
Sándor P, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005; 64(4): p. 713-5.
Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015; 18(4): p. 169-76.
Hagen K, Brenner E, Linde M, Gravdahl G, et al. Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study. Cephalalgia. 2015; 35(11): p. 987-95.
Page M, McKenzie J, Bossuyt P, Boutron I, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: p. n71.
Hajihashemi P, Askari G, Khorvash F, Reza Maracy M, Nourian M. The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Cephalalgia. 2019; 39(5): p. 648-654.
Dahri M, Hashemilar M, Asghari-Jafarabadi M, Tarighat-Esfanjani A. Efficacy of coenzyme Q10 for the prevention of migraine in women: A randomized, double-blind, placebo-controlled study. European Journal of Integrative Medicine. 2017; 16: p. 8-14.
Parohan M, Sarraf P, Javanbakht M, Foroushani AR, Ranji- Burachaloo S, Djalali M. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Nutr Neurosci. 2021; 24(4): p. 317-326.
Gaul C, Diener H, Danesch U, Migravent® SG. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain. 2015; 16: p. 516.
Nattagh-Eshtivani E, Dahri M, Hashemilar M, Tarighat-Esfanjani A. The effect of Coenzyme Q10 supplementation on serum levels of lactate, pyruvate, matrix metalloproteinase 9 and nitric oxide in women with migraine. A double blind, placebo, controlled randomized clinical trial. European Journal of Integrative Medicine. 2018; 21: p. 70-76.
Dahri M, Tarighat-Esfanjani A, Asghari-Jafarabadi M, Hashemilar M. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr Neurosci. 2019; 22(9): p. 607-615.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Angelo Israel García Purcachi , Genesis Elena Franco Aguayo , Denisse Katherine Pinzon Moran, Jimmy Fernando Yaguana Torres , Christian David Cevallos Mendoza, Israel Rollin Guerrero Ulloa (Autor/a)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Los artículos publicados en la revista se distribuyen bajo la licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esta licencia permite a terceros descargar, copiar, distribuir, adaptar y reutilizar una obra, incluso con fines comerciales, siempre que se otorgue el crédito adecuado al autor original.
